Merck, Palantir partner new healthcare initiatives

Merck, Palantir partner for new healthcare initiatives

10:45 AM, 13th January 2017
Merck, Palantir logo

PALO ALTO, US/ DARMSTADT, GERMANY: Merck KGaA announced a partnership with Palantir Technologies, a developer of the world's most sophisticated data integration and analysis software, headquartered in Palo Alto, California.

The partnership will leverage Palantir's advanced data analytics capabilities to help Merck better and more rapidly develop and deliver medicines to patients, commercialise new products, and improve patient outcomes. Initially, Merck will apply Palantir's technology to cancer treatment and patient services. Ultimately Merck plans to deploy Palantir's technology across all three of the company's business sectors healthcare, life science and performance materials.

The partnership will launch with three initiatives within the Healthcare business sector of Merck:

Medical research & drug development: The partnership will increase the precision of the drug development process by developing a collaborative data and analytics platform so that researchers of Merck can analyse real-world and bioinformatics data to understand the patients who may benefit most.

Global patient intimacy: The partnership will improve the experience of patients using products of Merck by utilising large-scale data sources to increase adherence and understand real-world drug efficacy.

Global supply chain: The data and analytics platform of Merck and Palantir will improve supply chain forecasting and agility in order to provide medicines to patients around the world with maximum speed and reliability.

Biomedical research generates unprecedented volumes of rapidly evolving data every day. But accessing, learning from, and expanding on those assets has become a huge bottleneck in scientists' ability to bring new innovations from the bench to the bedside. Through their combined expertise, Merck and Palantir will aim to harness the power locked inside that data for the benefit of patients.

"As a science and technology company, we are tackling the greatest challenges in healthcare, life science and performance materials. Now we are teaming up with Palantir since developing breakthrough technologies requires superior data analytics capabilities, and Palantir optimally complements our skills in that respect," said Stefan Oschmann, chairman of the executive board and CEO of Merck.

"At the heart of Palantir's mission is the desire to bring new tools to solve the world's most difficult problems. When something like cancer is killing 8.2 million people each year, we want to do everything we can to apply our technological expertise to the fight, alongside partners who have been there since the beginning. We are pleased to have found a partner that shares our values and vision," said Alexander Karp, founder and CEO of Palantir.

© Worldofchemicals news



Your Comments (Up to 2000 characters)
Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Related News

ExxonMobil makes new oil discovery offshore Guyana

IRVING, US: ExxonMobil Corporation declared a new oil discovery from its Payara-1 well offshore Guyana. Payara is ExxonMobil’s second oil discov ...

Read more
KBR bags industrial services contract by International Paper

HOUSTON, US: KBR Inc has been awarded a contract for maintenance, planning and industrial services by International Paper (IP), a global producer of r ...

Read more
Scientists tie the tightest knot ever from atom strings

MANCHESTER, UK: University of Manchester researchers have produced the most tightly knotted physical structure ever known – a scientific accompl ...

Read more
Eastman expands Avra performance fibres capacity in US

SALT LAKE CITY, US: Eastman Chemical Company said that it is expanding its Avra performance fibres production capacity, at the Unifi Manufacturing Inc ...

Read more
Monsanto, NRGene sign licensing agreement for genome analysis technology

ST LOUIS, US/NESS ZIONA, ISRAEL: Monsanto Company and NRGene have reached a non-exclusive, multi-year global licensing agreement on NRGene’s gen ...

Read more
Albemarle announces redemption of all outstanding 3 pc senior notes

CHARLOTTE, US: Albemarle Corporation said that it intends to redeem all of its outstanding 3 percent Senior Notes due 2019, issued by it on February 1 ...

Read more uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X